Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/6Y4 stock hub

FRA/6Y4 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/6Y4is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

278.5M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/6Y4FRA/6Y4

—

Loading chart…

In the news

Latest news · FRA/6Y4

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-47.2

P25 n/aP50 n/aP75 n/a

ROIC-29.7

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/6Y4 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

139

Groups with data

Currency

SEK

Showing 139 of 139 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Sweden
Country code	DE
Employees	36
Employees Change	7%
Employees Change Percent	24.14
Enterprise value	EUR 180.9M
Exchange	Frankfurt Stock Exchange
Financial currency	SEK
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 278.5M
Price	EUR 0.9
Price currency	EUR
Rev Per Employee	8,687.27x
Sic	2836
Symbol	fra/6Y4
Website	https://www.vicorepharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-15.53%
EV Earnings	-4.18x
P/B ratio	3.08x
P/S ratio	866.51x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	370.57%
Gross Profit	EUR 1.2M
Gross Profit Growth	5.32%
Gross Profit Growth Q	1,756.5%
Net Income	EUR -43.2M
Pretax Margin	-13,452.5%
Profit Per Employee	EUR -1.2M
ROA	-27.61
Roa5y	-34.77
ROCE	-48.08
ROE	-47.19
Roe5y	-62.78
ROIC	-29.66

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	29.44%
Cagr3y	-19.17%
Cagr5y	-16.36%
Revenue Growth	-41.17x
Revenue Growth Q	-32.51x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0
Assets	EUR 98.2M
Cash	EUR 96.6M
Current Assets	EUR 98.8M
Current Liabilities	EUR 7.8M
Equity	EUR 90.3M
Liabilities	EUR 7.9M
Long Term Assets	EUR -669,286
Long Term Liabilities	EUR 79,614
Net Cash	EUR 96.6M
Net Cash By Market Cap	EUR 34.68
Net Cash Growth	1.05%
Net Debt Equity	EUR -1.07
Tangible Book Value	EUR 90.3M
Tangible Book Value Per Share	EUR 0.32

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	12.69
Net Working Capital	EUR -6.4M
Quick ratio	12.57
Working Capital	EUR 90.2M
Working Capital Turnover	EUR 0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-50.54%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	29.41%
200-day SMA	0.95
3Y total return	-47.21%
50-day SMA	0.88
50-day SMA vs 200-day SMA	50under200
5Y total return	-59.07%
All Time High	17.75
All Time High Change	-94.92%
All Time High Date	2020-07-31
All Time Low	0.52
All Time Low Change	73.13%
All Time Low Date	2025-04-16
ATR	0.02
Ch YTD	-10.52
High	0.9
High52	1.18
High52 Date	2025-10-01
High52ch	-23.69%
Low	0.9
Low52	0.64
Low52 Date	2025-07-16
Low52ch	40.94%
Ma50ch	2.2%
Price vs 200-day SMA	-5.05%
RSI	52.27
RSI Monthly	39.44
RSI Weekly	48.26
Sharpe ratio	0.67x
Sortino ratio	1.22
Total Return	-50.54%
Tr YTD	-10.52
Tr1m	1.12%
Tr1w	1.46%
Tr3m	-1.96%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -43.5M
Operating margin	-13,530

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	198,621,158%
Shares Insiders	4.88%
Shares Institutions	33.87%
Shares Qo Q	8.89%
Shares Yo Y	50.54%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	0x
Bv Per Share	0.32
Ch1m	1.12
Ch1w	1.46
Ch1y	29.41
Ch3m	-1.96
Ch3y	-48.63
Ch5y	-60.18
Ch6m	-3.53
Change	-4.35%
Change From Open	0
Close	0.94
Days Gap	-4.35
Earnings Date	2026-05-06
EBIT	EUR -43.5M
EPS	EUR -0.17
F Score	2
Financing CF	39,237,178
Fiscal Year End	December
Founded	2,000
Income Tax	EUR 7,838
Investing CF	-32,381,991
Is Primary Listing	0
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Ma150	0.95
Ma150ch	-5.07%
Ma20	0.89
Ma20ch	1.57%
Net CF	-30,807,743
Next Earnings Date	2026-08-21
Open	0.9
Price Date	2026-05-08
Ptbv Ratio	3.08
Revenue	321,429x
Tax By Revenue	2.44x
Tr6m	-3.53%

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/6Y4 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/6Y4 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/6Y4?

Insider, institutional, and short-interest positioning.

Institutional ownership

+33.9%

Share of float held by funds and institutions

Insider ownership

+4.9%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+50.5%

Negative means the company is buying back shares.

Technical

FRA/6Y4 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.3

Neutral momentum band

Price vs 200-day MA

-5.1%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.67

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/6Y4

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/6Y4 stock rating?

fra/6Y4 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/6Y4 analysis?

The full report lives at /stocks/fra/6Y4/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/6Y4?

The latest report frames fra/6Y4 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/6Y4 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.